Kymera Announces First Patient Dosed in Asthma Drug Trial
Kymera has begun dosing in BREADTH, a global, randomized, double-blind, placebo-controlled Phase 2b study of KT-621 in approximately 264...
eClinical Tech News
FDA Clears Scancell’s Phase 3 Trial for Advanced Melanoma
Updated Phase 2 data show a 74% progression-free survival rate at 16 months in the target population for iSCIB1+...
Longeveron Gets FDA Meeting for Pivotal HLHS Phase 2 Trial
Longeveron plans a third-quarter 2026 top-line readout for ELPIS II, a 40-patient, 12-site pivotal Phase 2b trial of laromestrocel...
LB Pharma Begins Phase 2 Trial for Bipolar Depression Drug
LB Pharmaceuticals has initiated ILLUMINATE-1, a U.S.-only, six-week, outpatient Phase 2 trial of LB-102 in bipolar I depression, randomizing...
First Patient Dosed in Phase 3 Ibsrela Constipation Study
First patient dosed in ACCEL, a 700‑patient, 26‑week, randomized, double‑blind, placebo‑controlled Phase 3 trial assessing twice‑daily tenapanor (IBSRELA) in...
FDA Victory: Scancell’s Pioneering Melanoma Trial Cleared
Updated Phase 2 data point to a 74% progression-free survival rate at 16 months for iSCIB1+ added to ipilimumab...
Briacell Trial Shows Remarkable Metastatic Cancer Survival
BriaCell reported a 52% one-year and 32% two-year survival rate in a Phase 2 cohort of heavily pretreated metastatic...
Opus Genetics Launches Gene Therapy Trial for Blindness
Opus Genetics will launch a clinical trial of OPGx-MERTK, an adeno-associated virus gene therapy for MERTK-related retinitis pigmentosa, in...
UVA’s Pioneering Trial Offers Hope for Sepsis Lung Failure
The University of Virginia has opened a first-in-human program for hCitH3-mAb, a monoclonal antibody intended to neutralize citrullinated histone...
Vagus Nerve Device Studied as Adjunctive PTSD Treatment
The initiative will enroll up to 40 adults with PTSD for 12 weeks of adjunctive treatment with gammaCore Sapphire,...